Carmex Cold Sore Treatment Claims Exceed Monograph Limit In NAD Review
This article was originally published in The Rose Sheet
Executive Summary
Carma Labs’ Carmex Cold Sore Treatment claims did not mirror language in two OTC monographs for its active ingredients, the National Advertising Division says in a review of packaging and advertising claims challenged by GlaxoSmithKline's consumer business.
You may also be interested in...
Boots' Symptoms Claim For Dual Defence Not A Prevention Pitch – UK Regulator
Boots UK’s display ad for its Dual Defense cold and flu symptom nasal spray was unlikely to deceive consumers to think it could prevent infection, UK Advertising Standards Authority says, which found that text in a poster ad sufficiently "conceptualized" the claim.
Cold Sore Ad Claims Review Poses Test For OTC Monograph Indications
Council of Better Business Bureaus forwards review of ad claims for Aubio Life Sciences' monograph cold sore treatment to US FDA and FTC, after firm rejected advice to discontinue certain claims. Initial challenge was brought by GSK, which markets an NDA cold sore product.
Cold Sore Ad Claims Review Poses Test For OTC Monograph Indications
Council of Better Business Bureaus forwards review of ad claims for Aubio Life Sciences' monograph cold sore treatment to US FDA and FTC, after firm rejected advice to discontinue certain claims. Initial challenge was brought by GSK, which markets an NDA cold sore product.